Ultragenyx Pharmaceutical: Recent Move in Context

Ultragenyx Pharmaceutical (RARE) has drawn fresh attention after its recent trading, with the stock closing at US$26.13. Investors are weighing this price against the company’s mixed return profile across the past year and the past 3 months.

The recent move to US$26.13 comes after a 12.87% 1 month share price return and a 10.72% year to date share price return, set against a 27.38% 1 year total shareholder return loss. This indicates that short term momentum is building while longer term holders remain under pressure.

If Ultragenyx’s recent swing has you thinking more broadly about opportunities in healthcare and biotech, it could be worth scanning for other companies exposed to medical AI through 35 healthcare AI stocks

With Ultragenyx trading at US$26.13 against recent losses over 1 and 5 years, plus an intrinsic discount figure of 0.90, you have to ask: is there real value on offer here, or is the market already pricing in future growth?

Most Popular Narrative: 50.2% Undervalued

With Ultragenyx closing at $26.13 against a narrative fair value of $52.45, the prevailing view is that the stock trades at a steep discount, hinging on its rare disease and gene therapy pipeline.

The accelerating global identification and diagnosis of rare diseases, supported by advancements in genomics and genetic testing, are expanding the addressable patient pool for Ultragenyx's existing and future therapies, which should drive sustained long-term revenue growth.

Healthcare payers and regulatory agencies are increasingly recognizing the value of orphan drugs, as evidenced by faster development timelines (FDA Breakthrough Therapy designation for GTX-102) and ongoing pricing/reimbursement wins in regions like Latin America and EMEA, supporting robust revenue streams and pricing power over the next several years.

Want to see what underpins that gap between price and fair value? The narrative leans on rapid revenue expansion, margin improvement, and a punchy future earnings multiple. Curious which specific expectations have to land for this $52.45 figure to hold up?

Result: Fair Value of $52.45 (UNDERVALUED)

However, this upbeat story can quickly change if regulatory setbacks around key gene therapies or ongoing net losses of US$609 million strain funding and delay progress.

Next Steps

With sentiment in this article mixed between pressure and potential, it makes sense to move quickly and test the assumptions yourself by weighing up the 2 key rewards and 3 important warning signs.

Ready to Find More Investment Ideas?

If Ultragenyx has caught your eye, do not stop here. Broader opportunities across sectors could fit your goals even better, so keep expanding your watchlist.

• Target long term stability by checking companies in the solid balance sheet and fundamentals stocks screener (44 results) that may better withstand shocks and funding pressures.
• Hunt for potential mispricings using the 51 high quality undervalued stocks to spot stocks the market might be overlooking right now.
• Build a cash flow focused portfolio by reviewing income ideas in the 12 dividend fortresses and see which yields could complement your growth holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.